Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2013 (2013), Article ID 196894, 7 pages
Research Article

Demethylation of Cancer/Testis Antigens and CpG ODN Stimulation Enhance Dendritic Cell and Cytotoxic T Lymphocyte Function in a Mouse Mammary Model

1Department of Hematology, Chinese PLA General Hospital, Beijing 100853, China
2Department of Oncology, The First Affiliated Hospital of Chinese PLA General Hospital, Beijing 100048, China
3Department of Pharmacy, The First Affiliated Hospital of Chinese PLA General Hospital, Beijing 100048, China
4Department of Hematology, China-Japan Friendship Hospital, Beijing 100029, China
5No. 535 Hospital of Chinese People’s Liberation Army, Huaihua, Hunan 418000, China

Received 28 April 2013; Accepted 2 August 2013

Academic Editor: Anne Hamburger

Copyright © 2013 Jun-Zhong Sun et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Background. Cancer/testis antigens (CTAs) are ideal targets for cancer immunotherapy in virtue of their restricted expression profile in normal tissues. However, CTA-targeted immunotherapy has been rather disappointing clinical setting for CTAs are downregulated by cytosine-phosphate-guanosine (CpG) methylation in their promoter regions, so that tumor cells have low immunogenicity. Methods. We reinduced mouse CTA P1A through demethylation process and generated P1A-specific cytotoxic lymphocytes (CTLs) by immunizing BALB/c (H- ) mice with dendritic cells pulsed with a P1A-specific peptide and CpG oligodeoxynucleotide (ODN) immune adjuvant. Results. We found that demethylation and CpG ODN immune adjuvant stimulation facilitated DC maturation and enhanced the allogenic capacity of P1A-specific CTLs against target cells both in vitro and in vivo. Conclusions. Our results suggested that CTA induction and immune adjuvant stimulation is a feasible strategy in cancer immunotherapy.